RxDoctor Payments Data

Joseph Bruckert, MD

Family Medicine · Cary, NCNPI 1306993019

Payments from drug & device makers

$13,771in general payments, 2019–2025

Across 853 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Amgen$984
  • Boehringer Ingelheim$918
  • Pfizer$565
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$3002%
  • Food & beverage$13,40897%
  • Education$620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,771 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$106,508
Medicare patients
336
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$57,362
OzempicSemaglutide29$49,430
TrulicityDulaglutide22$39,330
Synjardy XrEmpagliflozin/Metformin Hcl24$35,168
FarxigaDapagliflozin Propanediol26$31,301
EliquisApixaban21$29,691
XareltoRivaroxaban17$22,115
VascepaIcosapent Ethyl18$18,764
Irbesartan154$4,680
Rosuvastatin Calcium379$4,420
Levothyroxine Sodium173$2,168
SynthroidLevothyroxine Sodium23$2,021
Raloxifene Hcl33$1,943
Atorvastatin Calcium126$1,683
Pravastatin Sodium71$1,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$918$92,53078 claims
Novo NordiskOzempic$2,407$49,43029 claims
Lilly USA, LLCTrulicity$555$39,33022 claims
AstraZenecaFarxiga$1,045$31,30126 claims
PfizerEliquis$565$29,69121 claims
Johnson & JohnsonXarelto$489$22,11517 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$54$2,168173 claims
AbbVieSynthroid$2,215$2,02123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →